ATM is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA1 is altered in 3.64% of high grade fallopian tube serous adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 9 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 6 are open and 3 are closed. Of the trials that contain BRCA1 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

BRCA2 is altered in 1.82% of high grade fallopian tube serous adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 9 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 6 are open and 3 are closed. Of the trials that contain BRCA2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

BRIP1 is altered in 1.82% of high grade fallopian tube serous adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is altered in 3.64% of high grade fallopian tube serous adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLE is altered in 1.82% of high grade fallopian tube serous adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is altered in 3.03% of high grade fallopian tube serous adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 87.3% of high grade fallopian tube serous adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].